Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) - Sanofi
Nicolas Dumas - Management Consultant | Bain & Company
Sally Bain - Senior Director, Global Media Relations - Sanofi | LinkedIn
Media Contacts - Sanofi
Sanofi adds first vaccine candidate against acne to its R&D pipeline with the take over of an Austrian privately held biotechnology firm | EuropaWire.eu | The European Union's press release distribution &
Sanofi Goes Big with $1 Billion Immuno-Oncology Buy | BioSpace
Media Contacts - Sanofi
Media Contacts - Sanofi
Sanofi makes $3.2B bet on mRNA by acquiring partner Translate Bio - Boston Business Journal
Sally Whiting Bain (@sbain09) / Twitter
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) - Sanofi
Anthony Jones - Bain External Advisor - Bain & Company | LinkedIn
Media Contacts - Sanofi
Sanofi partners Bain Capital-backed Emcure for oncology drugs portfolio in India
Media Contacts - Sanofi
Sanofi and Swansea collaborate on UK's first | EurekAlert!
Media Contacts - Sanofi
Media Update
